Deep Brain Stimulation for the Treatment of Refractory Bipolar Disorder
1 other identifier
interventional
6
1 country
1
Brief Summary
Bipolar Disorder (BD) is among the most comon and challenging conditions in psychiatry. Although episodes of mania and hypomania define the different types of the disorder, the clinical picture is one dominated by depressed mood and agitation. The mainstay of BD treatment has thus far been pharmacologic, but many patients remain severely disabled by their condition, despite the best available medical treatment. The successful use of deep brain stimulation (DBS) in movement disorders, and its promising results in major depressive disorder (MDD), has led researchers to consider its use in highly selected refractory cases of BD. Evidence form the imaging and circuitry literature suggests that similar underlying dyfunctional anatomic structures subserve both MDD and BD, indicating that modulation of key structures, can lead to an amelioration of symptoms and mood stabilization. Here, we propose a phase I clinical trial to evaluate the safety of DBS in BD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2011
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2011
CompletedFirst Submitted
Initial submission to the registry
November 15, 2011
CompletedFirst Posted
Study publicly available on registry
November 22, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2014
CompletedOctober 30, 2019
October 1, 2019
3.1 years
November 15, 2011
October 28, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Hamilton Rating Scale for Depression
Hamilton Depression Rating Scale (HAMD), Montgomery-Åsberg Depression Rating Scale (MADRS)
Change from baseline in depression scores at 3 months, 6 months and 12 months
Secondary Outcomes (2)
Young Mania Rating Scale
Change from baseline in manic, hypomanic scores at 3 months, 6 months and 12 months
Questionnaires-Quality of Life
Change from baseline in quality of life scores at 3 months, 6 months and 12 months
Study Arms (1)
Deep Brain Stimulation
EXPERIMENTALDeep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
Interventions
Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
Eligibility Criteria
You may qualify if:
- Male or Female patients between the age of 30-60
- DSM IV-TR diagnosis of Bipolar Disorder I or II
- Diagnosis for \>12 months with a HRSD-17 score of at least 20
- Failure of medical therapy, defined as follows:
- a. Failure of a minimum of two (2) first line as well as two (2) second line treatments for bipolar mania and depression
- No neurological disease
- No other active Axis I or Axis II co-morbidity that is the focus of clinical attention, as defined by the Mini International Neuropsychiatric Interview (MINI)
- No substance abuse or substance use disorder for minimum of three months prior to study
- Able to give informed consent
- Able to comply with all testing and follow-up visit requirements defined by the Study Protocol
- Mini mental status examination (MMSE) score \>25
- Pre-menopausal women must agree to use acceptable methods of birth control (radiation risk of PET)
You may not qualify if:
- History of psychosis, or psychotic episodes
- Alcohol or substance dependence or abuse within 6 months, excluding nicotine or caffeine.
- Current suicidal ideation, plan or intent for self-harm.
- A suicide attempt in the past 1 year
- Major medical illness, cardiac pacemaker/defibrillator, and other implanted stimulator
- Likely to relocate or move to a location distant from the study site within one year of enrollment
- Any contraindication to MRI or PET scanning
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andres M Lozano, MD PhD
University Health Network, Toronto
- PRINCIPAL INVESTIGATOR
Roger McIntyre, MD
University Health Network, Toronto
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Neurosurgeon, Professor of Surgery
Study Record Dates
First Submitted
November 15, 2011
First Posted
November 22, 2011
Study Start
May 1, 2011
Primary Completion
June 1, 2014
Study Completion
June 1, 2014
Last Updated
October 30, 2019
Record last verified: 2019-10